Oramed Pharmaceuticals Inc.
ORMP
$2.33
$0.031.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -100.00% |
| SG&A Expenses | 1.09% | -56.25% | -35.97% | 23.22% | -32.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.27% | 6.77% | -29.79% | -49.57% | -62.80% |
| Operating Income | 7.27% | -6.77% | 17.30% | 43.13% | 60.20% |
| Income Before Tax | -173.58% | -463.61% | 925.44% | 142.48% | 252.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -176.71% | -498.11% | 800.99% | 142.48% | 252.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -75.00% | -62.90% | -93.28% | -99.07% | -79.27% |
| Net Income | -176.40% | -508.91% | 871.52% | 145.24% | 256.10% |
| EBIT | 7.27% | -6.77% | 17.30% | 43.13% | 60.20% |
| EBITDA | 6.80% | -6.97% | 17.60% | 43.80% | 60.67% |
| EPS Basic | -176.12% | -501.88% | 857.24% | 144.34% | 251.87% |
| Normalized Basic EPS | 22.86% | -473.78% | 1,051.72% | 39.61% | 63.64% |
| EPS Diluted | -181.22% | -501.88% | 833.33% | 144.34% | 248.18% |
| Normalized Diluted EPS | 20.83% | -473.78% | 1,037.36% | 40.59% | 64.57% |
| Average Basic Shares Outstanding | 0.36% | 1.11% | 1.83% | 1.98% | 2.79% |
| Average Diluted Shares Outstanding | -2.07% | 1.11% | 3.39% | 3.80% | 5.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |